Want to join the conversation?
Boehringer Ingelheim and $LLY announced plans to conduct two outcome trials investigating diabetes medicine Jardiance (empagliflozin) for the treatment of people with chronic heart failure. The trials are targeted to begin within next 12 months and are planned to enroll people with chronic heart failure both with and without type 2 diabetes.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.